ImmunityBio’s lawsuit clock keeps ticking

Another day, another lawsuit reminder

ImmunityBio is getting the kind of attention every public company loves to avoid: a class action notice. Berger Montague says it’s representing investors who bought shares during the Jan. 19 to Mar. 24, 2026 window, and the clock is now ticking toward a May 26 lead-plaintiff deadline.

Why you should care

This isn’t just legal boilerplate tossed into the void. Securities-fraud cases can hang over a stock like a rain cloud at a picnic — especially in biotech, where one bad headline can make investors skittish fast.

• If the lawsuit gains steam, legal costs and management distraction can pile up.
• The complaint period overlaps with a pretty specific stretch of trading, which gives the case a clearer target.
• Even if nothing changes overnight, repeated lawsuit notices tend to keep sentiment muddy.

Same story, different law firm

If this feels familiar, that’s because it basically is. ImmunityBio has been collecting lawsuit notices like baseball cards over the past couple of weeks, and this Berger Montague reminder is another turn of the same legal crank.

Big picture: when a stock keeps showing up in class-action headlines, investors don’t need a gavel to feel the pressure — they just need a chart and a memory.